Drug Profile
Research programme: HIV protease inhibitor-polymer conjugates - Nektar Therapeutics
Alternative Names: HIV PI-polymer conjugates - Nektar Therapeutics; NKTR-140Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Class Drug conjugates; Small molecules
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA
- 03 Mar 2010 Preclinical trials in HIV infections in USA (unspecified route)